A novel MLL2 gene mutation in a Korean patient with Kabuki syndrome

Soo Jin Kim, MD, Sung Yoon Cho, MD, Se Hyun Maeng, MD, Young Bae Sohn, MD, Su-Jin Kim, MD, Chang-Seok Ki, MD, Dong-Kyu Jin, MD

Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Kabuki syndrome (KS) is a rare genetic disease with a distinctive dysmorphic face, intellectual disability, and multiple congenital abnormalities. KS is inherited in an autosomal dominant manner. As the primary cause of KS, MLL2 mutations have been identified in 56–76% of affected individuals who have been tested, suggesting that there may be additional genes associated with KS. Recently, a few KS individuals have been found to have de novo partial or complete deletions of an X chromosome gene, KDM6A, which encodes a histone demethylase that interacts with MLL2. Nevertheless, mutations in MLL2 are the major cause of KS. Although there are a few reports of KS patients in Korea, none of these had been confirmed by genetic analysis. Here, we report a case of a Korean patient with clinical features of KS. Using direct sequencing, we identified a frameshift heterozygous mutation for MLL2: (c.5256_5257delGA;p.Lys1753Alafs*34). Clinically, the patient presented with typical facial features, and diagnosis of KS was based on the diagnostic criteria. While KS is a rare disease, other malformations that overlap with those found in individuals with KS are common. Hence, the diagnosis of KS by mutational analysis can be a valuable method for patients with KS-like syndromes. Furthermore, in the near future, other genes could be identified in patients with KS without a detectable MLL2 mutation.

Key words: Kabuki syndrome, MLL2 mutation, KDM6, KS-associated genes

Introduction

Kabuki syndrome (KS; OMIM 147920) was first described in 1981 by Niikawa et al. and Kuroki et al. It has an estimated incidence of 1 in 32,000 and approximately 400 cases have been reported worldwide. In Korea, in 1991, Park et al. first reported KS patient and from 1991 to date, about 10 KS patients have been reported. However, none of these demonstrated causative genetic abnormalities. Consensus of clinical diagnostic criteria for KS have not been established. The main clinical characteristics of KS include five cardinal manifestations, as defined by Niikawa et al.: typical dysmorphic facial features, skeletal anomalies including spinal column abnormalities and brachydactyly, dermatoglyphic abnormalities such as persistent fetal finger pads, mild to moderate intellectual disability and postnatal growth deficiency. The typical facial characteristics observed in KS include elongated palpebral fissures with eversion of the lateral third of the lower eyelid, arched or nicked eyebrows with the lateral third displaying sparseness or notching, short columella with depressed nasal tip and large, and prominent or upped ears.

A gene causing KS was identified through whole exome sequencing by Ng et al., who reported mutations in MLL2 in 66% of 53 patients with KS. In five published series, mutations in MLL2 were identified in 56–76% of 53 patients with KS. However, the role of MLL2 in the pathogenesis of KS remains to be elucidated.
in MLL2 were found in 56–76% of KS patients. The recent search for additional causative genes revealed KDM6A deletion in three KS patients among 22 MLL2 mutation-negative patients, and none KS patients among 120 MLL2 mutation-negative patients. However, until now, the major cause of KS is known to be MLL2 gene mutations. In this report, we describe a case of a novel MLL2 gene mutation in a KS patient with typical distinctive facial features.

**Case report**

The male patient was born at 40 weeks gestation by spontaneous vaginal delivery to a 27-year-old G0P0 mother and a 29-year-old father. The parents were nonconsanguineous and healthy. The pregnancy and labor were uncomplicated. There was no history of fever, rash, spotting, tobacco, alcohol, illicit drug use, or X-ray exposure during pregnancy. At birth, the patient had microcephaly (<10th percentile) but no anatomical anomalies. He was admitted to a neonatal intensive care unit for 2 weeks due to transient respiratory difficulty. At 18 months of age, he first visited our clinic due to developmental delay. His height, weight, and head circumference were 77.4 cm (10–25th percentile), 11 kg (25–50th percentile), and 43.4 cm (5–10th percentile), respectively. He could stand up with support at 15 months of age and walked alone at 25 months of age. His speech was delayed and at 27 months of age, he first said “mama”. He showed long palpebral fissures with lateral eversion of the lower eyelid, long eyelashes, arched eyebrows with lateral thinning, and a depressed nasal tip. He had brachydactyly and prominent finger pads of bilateral third and fourth fingers. His intelligence quotient was estimated at 53 by Korean-Wechsler Preschool and Primary Scale of Intelligence, which meant moderate mental retardation (0.05th percentile). Spine X-ray showed butterfly vertebra at the 3rd thoracic spine, and echocardiography showed no cardiac anomalies except bicuspid aortic valve. Neurologic examinations showed no abnormal findings. He suffered from recurrent otitis media. At 11 years of age, his height, weight, and head circumference were 131.7 cm (<3rd percentile), 48.6 kg (75–90th percentile), and 55.5 cm (95–97th percentile), respectively. His chromosome was normal, 46, XY, and other laboratory findings including immunoglobulin, insulin, fasting glucose, cholesterol and thyroid hormone (TSH and free T4) were normal.

As our patient had typical facial features, skeletal anomalies and postnatal growth deficiency such as height 2 standard deviations, we diagnosed him as KS by clinical findings. After informed consent had been obtained, we performed molecular genetic testing for the MLL2 gene. A novel heterozygous MLL2 mutation (c.5256_5257delGA;p.Lys1753Alafs*34) was identified. However, no genetic mutations were detected in both parents (Fig. 1).

**Fig. 1.** Mutation analysis of the MLL2 gene. Direct sequencing chromatograms displaying the heterozygote frameshift mutation for MLL2 (c.5256_5257delGA,p.Lys1753Alafs*34) in exon 22 (arrow) in a patient (A and B), (A) Patient: forward strand, (B) patient: reverse strand, (C) father, and (D) mother.
Discussion

MLL2 is 36.3 kb in size and comprises 54 exons. It is located at chromosome 12q13 and encodes a histone methyltransferase that regulates the transcription of a diverse set of genes involved in embryogenesis and development. Recently, de novo partial or complete deletion of the Xp11.23 located gene, lysine demethylase 6A, KDM6A, has been identified in three KS patients, confirming the genetic heterogeneity of the disease. Like MLL2, KDM6A plays a role in embryogenesis and development. KDM6A and MLL2 act together in the epigenetic control of transcriptionally-active chromatin.

Taking several studies together, the majority of MLL2 mutations were nonsense and frameshift. Hannibal et al. found MLL2 mutations in 74% of 110 KS patients, including 37 nonsense, 22 frameshifts, 16 missense, 3 in-frame deletions/duplications and 3 splice-site mutations; there were 10 sites at which recurrent mutations were observed. Li et al. found MLL2 mutations in 56% of 34 KS patients and 1 recurrent missense mutation (c.15461G>A). Micale et al. found MLL2 mutations in 73% of 62 KS patients and 3 recurrent nonsense, 3 frame shift mutations and 1 splice site variant. Missense mutations have been reported but are relatively infrequent. In prior studies, mutations were distributed throughout the gene, however, there appeared to be some exons in which mutations were identified with considerably higher frequency such as exons 39 and 48. It will be important in future studies to define that there might be mutational hotspot of particular relevance.

Comparison of clinical characteristics of MLL2 mutation-negative versus MLL2 mutation–positive cases allows us to explore both the relationship between MLL2 genotype and phenotype. Overall, some authors found growth retardation and distinctive facial features more frequently in MLL2 mutation–positive cases. However many studies found no significant different characteristics between MLL2 mutation-positive cases from MLL2 mutation–negative cases, except renal anomalies (single fused kidneys, ureteropelvic junction obstruction, duplication of the collecting system, and hydronephrosis) and short stature. Renal anomalies and short stature were more common in MLL2 mutation–positive cases. In comparison with other MLL2 positive patients, our patient has short stature (<3rd percentile), however, he is overweighted (75–90th percentile) and he has macrocephaly (95–97th percentile).

Diagnosis of KS is mainly clinical, based on a combination of distinctive dysmorphic face, intellectual disability, and multiple congenital abnormalities. There are KS-like syndromes such as X-linked mental-retardation syndrome by defects of histone methylation which shows intellectual disability and malformations (e.g., cleft lip/palate). The histone methylases and histone demethylases have been implicated in multiple-anomaly syndromes. In clinical practice, having the molecular confirmation of the clinical and biochemical diagnosis helps differential diagnosis. In addition, identification of pathogenic mutations in MLL2 or KDM6A has a role in patients with intellectual disability or characteristic malformations.

KS is inherited in an autosomal dominant manner. The proportion of KS caused by de novo mutations is unknown, but is likely high based on clinical experience. Each child of an individual with KS has a 50% chance of inheriting the mutation. Prenatal diagnosis for pregnancies at increased risk is possible if the disease-causing mutation in an affected family member is known.

In summary, one novel mutation (c.5256_5257delGA; p.Lys1753 Ala&34) was identified in a Korean patient with KS and it was revealed as a de novo mutation. The biological significance and pathogenicity of MLL2 in KS patients is not clearly demonstrated. Therefore, functionally-oriented studies are needed. Furthermore, other KS-associated genes need to be discovered.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

The study was supported by the Korea Healthcare Technology R&D Project funded by the Ministry for Health, Welfare, and Family Affairs, Republic of Korea (Grant number: A080588), and the Samsung Biomedical Research Institute (Grant numbers: C-A9-240-2), and the In-Sung Foundation for Medical Research.

References

1. Niikawa N, Matsuura N, Fukushima Y, Ohsawa T, Kajii T. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, and short stature in 10 patients. J Pediatr 1981;99:565–9.
2. Kuroki Y, Suzuki Y, Chyo H, Hata A, Matsui I. A new malformation syndrome of long palpebral fissures, large ears, depressed nasal tip, and skeletal anomalies associated with postnatal dwarfism and mental retardation. J Pediatr 1981;99:570–3.
3. Niikawa N, Kuroki Y, Kajii T, Matsuura N, Ishikiriyama S, Tonoki H, et al. Kabuki make-up (Niikawa-Kuroki) syndrome: a study of 62 patients. Am J Med Genet 1988;31:565–89.
4. Park SK, Park DK, Chung JT, Son CS, Dokgo YC. A case of Kabuki make-up syndrome. J Korean Med Assoc 1991;34:790–2.
5. Huit JK, Chung MS, Baek GH, Oh JH, Lee YH, Gong HS. Cleft hand in Kabuki make-up syndrome: case report. J Hand Surg Am 2011;36:653–7.
6. Kim NG, Kim HJ, Hwang JM. Strabismus and poor stereoacuity as-
associated with Kabuki syndrome. Korean J Ophthalmol 2011;25:136-8.
7. Ko JM, Hwang JM, Kim HJ. Phenotypic and cytogenetic delineation of six Korean children with Kabuki syndrome. J Genet Med 2010;7:37-44.
8. Lim HS, Ahn JH, Rho SS, Lew HM, Chang YH. A case of Kabuki syndrome with ocular manifestation. J Korean Ophthalmol Soc 2009;48:1728-30.
9. Ng SB, Bigham AW, Buckingham KJ, Hannibal MC, McMillin MJ, Gildersleeve HI, et al. Exome sequencing identifies MLL2 mutations as a cause of Kabuki syndrome. Nat Genet 2010;42:790-3.
10. Paulussen AD, Stegmann AP, Blok MJ, Tserpelis D, Posna-Velter C, Detisch Y, et al. MLL2 mutation spectrum in 45 patients with Kabuki syndrome. Hum Mutat 2011;32:E2018-25.
11. Li Y, Bogershausen N, Alanay Y, Simsek Kiper PO, Plume N, Keupp K, et al. A mutation screen in patients with Kabuki syndrome. Hum Genet 2011;130:715-24.
12. Micale L, Augello B, Fusco C, Selicorni A, Loviglio MN, Silengo MC, et al. Mutation spectrum of MLL2 in a cohort of Kabuki syndrome patients. Orphanet J Rare Dis 2011;6:38.
13. Hannibal MC, Buckingham KJ, Ng SB, Ming JE, Beck AE, McMillin MJ, et al. Spectrum of MLL2 (ALR) mutations in 110 cases of Kabuki syndrome. Am J Med Genet A 2011;155A:1511-6.
14. Lederer D, Grisart B, Digilio MC, Benoit V, Crespin M, Ghariani SC, et al. Deletion of KDM6A, a histone demethylase interacting with MLL2, in three patients with Kabuki syndrome. Am J Hum Genet 2012;90:119-24.
15. Priolo M, Micale L, Augello B, Fusco C, Zucchetti F, Ponzonera P, et al. Absence of deletion and duplication of MLL2 and KDM6A genes in a large cohort of patients with Kabuki syndrome. Mol Genet Metab 2012;107:627-9.
16. FitzGerald KT, Diaz MO. MLL2: a new mammalian member of the trx/MLL family of genes. Genomics 1999;59:187-92.
17. Dillon SC, Zhang X, Trievel RC, Cheng X. The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol 2005;6:227.
18. Issaeva I, Zonis Y, Rozovskaia T, Orlovsky K, Croce CM, Nakamura T, et al. Knockdown of ALR (MLL2) reveals ALR target genes and leads to alterations in cell adhesion and growth. Mol Cell Biol 2007;27:1889-903.
19. Banka S, Veeramachaneni R, Reardon W, Howard E, Bunstone S, Ragen N, et al. How genetically heterogeneous is Kabuki syndrome?: MLL2 testing in 116 patients, review and analyses of mutation and phenotypic spectrum. Eur J Hum Genet 2012;20:381-8.
20. Bokinni Y. Kabuki syndrome revisited. J Hum Genet 2012;57:223-7.